Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (331-340 of 584) with videos related to

Pageof 59
Sort By:
Cancer Treatment Reports|May 1, 1982
Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B studyP C Amrein, M Coleman, F Richards, et al.
Cancer|February 28, 2007
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemiaAhmed Aribi, Hagop M Kantarjian, Elihu H Estey, et al.
Haematologica|December 10, 2020
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemiaIman Abou Dalle, Ronald Paranal, Jabra Zarka, et al.
Blood|March 24, 2016
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyWei Wang, Jorge E Cortes, Guilin Tang, et al.
Veterinary Parasitology|January 29, 2013
Prevalence of Babesia microti-like infection in red foxes (Vulpes vulpes) from PortugalL Cardoso, H C E Cortes, A Reis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylateGloria N Mattiuzzi, Jorge E Cortes, Moshe Talpaz, et al.
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Cancer|December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseThomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Haematologica|May 2, 2024
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERNJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Blood|May 23, 2015
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1Sanam Loghavi, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, et al.
Pageof 59

Showing results (331-340 of 584) with videos related to

Sort By:
Pageof 59
Cancer Treatment Reports|May 1, 1982
Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B studyP C Amrein, M Coleman, F Richards, et al.
Cancer|February 28, 2007
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemiaAhmed Aribi, Hagop M Kantarjian, Elihu H Estey, et al.
Haematologica|December 10, 2020
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemiaIman Abou Dalle, Ronald Paranal, Jabra Zarka, et al.
Blood|March 24, 2016
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyWei Wang, Jorge E Cortes, Guilin Tang, et al.
Veterinary Parasitology|January 29, 2013
Prevalence of Babesia microti-like infection in red foxes (Vulpes vulpes) from PortugalL Cardoso, H C E Cortes, A Reis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylateGloria N Mattiuzzi, Jorge E Cortes, Moshe Talpaz, et al.
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Cancer|December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseThomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Haematologica|May 2, 2024
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERNJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Blood|May 23, 2015
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1Sanam Loghavi, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, et al.
Pageof 59